Opinion|Videos|January 3, 2025
Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
Panelists discuss how a patient who is neutropenic is given supportive care with GCSF, as do patients who have prolonged neutropenia, then that patient will be on antibiotic and antifungal prophylaxis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Given the patient’s history of frequent infections, how would you balance talquetamab’s efficacy with the need for infection control, and what supportive measures might you prioritize?
- How would you approach treatment sequencing if the patient progresses on talquetamab, and what criteria would you use to determine the next line of therapy?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5